Surrozen raises $175M, to focus on ophthalmology; CBC Group has a new $1B fund

Plus, news about CG Oncology, Opus Genetics and Valneva: Surrozen’s pivot and capital raise: The South San Francisco drug developer is scrapping clinical development in severe alcohol associated hepatitis and instead ...